A pragmatic randomized trial to evaluate the vaccine effectiveness of bivalent RSV prefusion F vaccine for preventing RSV hospitalizations in adults (DAN-RSV): Trial design update - 08/07/26
ABSTRACT |
Background |
Respiratory syncytial virus (RSV) is a major cause of respiratory morbidity in adults, particularly among older individuals and those with comorbidities. The DAN-RSV trial was initiated to evaluate bivalent RSV prefusion F (RSVpreF) vaccine effectiveness in preventing RSV-related hospitalizations.
Methods |
DAN-RSV is a large-scale, pragmatic, randomized clinical trial that enrolled participants during the 2024/2025 (Danish adults aged ≥60 years) and 2025/2026 (adults aged ≥18 years in Denmark and Galicia, Spain) Northern hemisphere winter seasons. In Denmark, nationwide registries and the national electronic messaging system were used to identify and recruit eligible citizens; individuals could provide electronic informed consent remotely or in-person. In Galicia, participants were recruited via text message invitations and consented on-site.
Results |
During the initial 2024/2025 season, 131,379 Danish adults aged ≥60 years were enrolled. Following lower-than-expected event accrual and expansion of the EU indication to adults 18 years and older, the trial was extended to continue enrollment of adults aged ≥18 years across Denmark and Galicia, Spain during the 2025/2026 RSV season. Key protocol updates include expansion of the eligibility criteria to adults aged ≥18 years, inclusion of an additional study site within the integrated public healthcare infrastructure of Galicia, Spain, and an increase in the planned sample size to up to approximately 690,000 participants across both seasons. The randomization strategy (1:1 to RSVpreF vaccine or no vaccine), primary endpoint (RSV-related respiratory tract disease hospitalization), and statistical framework, including intention-to-treat analyses and hierarchical testing, remain unchanged.
Conclusion |
The extension of the DAN-RSV trial is expected to improve statistical precision, enhance generalizability, and strengthen the robustness of the effect estimates. The updated design will provide reliable randomized evidence on bivalent RSVpreF vaccine effectiveness to inform clinical and public health decision-making.
Le texte complet de cet article est disponible en PDF.Plan
Vol 300
Article 107497- octobre 2026 Retour au numéro
Article précédent
- Progression of bicuspid-related aortopathy in patients undergoing transcatheter aortic valve implantation: Rationale and design of the international, multicenter PROSPERO-TAVI registry
- Giuliano Costa, Giulia Laterra, Sofia Sammartino, Ole De Backer, Yuheng Jia, Thomas Pilgrim, Tomii Daijiro, Matteo Montorfano, Francesco Ancona, Barbara Bellini, Simon Redwood, Tiffany Patterson, Ran Kornowski, Ashraf Hamdan, Darren Mylotte, Paolo Alberto Del Sole, Francesco Saia, Tullio Palmierini, Francesco Bedogni, Caterina Gandolfo, Stefano Cannata, Philippe Garot, Emmanuel Gall, Marco De Carlo, Marco Angelillis, Sebastiano Immè, Corrado Tamburino, Antonio Mangieri, Francesco Tartaglia, Luis Nombela, Ignacio Amat Santos, Mario Garcia Gomez, Guilherme Attizzani, Marco Frazzetto, Mariachiara Calì, Kevin Millar, John Webb, Marco Barbanti
- Community-based recruitment with ankle brachial index testing to identify peripheral artery disease participants for randomized clinical trials
- Mary M. McDermott, Madeline D. Cetlin, Kathryn J. Domanchuk, Shujun Xu, Mary O. Whipple, Tamar Polonsky, Michael H. Criqui, Jack M. Guralnik, Lu Tian, Lihui Zhao, Karen J. Ho, Philip Greenland, Diane Treat-Jacobson
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?